Peer-influenced content. Sources you trust. No registration required. This is HCN.

Neurology AdvisorDoes Anti-CD20 Treatment Affect Response to COVID-19 Vaccines in Patients With Multiple Sclerosis? Review of a Pilot Study

In this Journal Club discussion, among participants in the vaccine-CD20-vaccine cohort, 100% of participants experienced a measurable response to a third dose of a COVID-19 vaccine compared with 18% in the CD20-vaccine cohort.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form